206 related articles for article (PubMed ID: 34920340)
21. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
[TBL] [Abstract][Full Text] [Related]
22. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
23. A neutrophilic dermatosis following treatment of myelofibrosis with ruxolitinib: An emerging phenomenon?
Jiang M; Tran AK; Marshman G
Australas J Dermatol; 2021 Nov; 62(4):e607-e609. PubMed ID: 34529266
[No Abstract] [Full Text] [Related]
24. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
25. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
26. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Gerds AT; Yu J; Scherber RM; Paranagama D; Kish JK; Visaria J; Singhal M; Verstovsek S; Pemmaraju N
Acta Haematol; 2022; 145(4):448-453. PubMed ID: 35008087
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of the effect of gene mutations on the efficacy of ruxolitinib in patients with myelofibrosis based on second-generation sequencing technology].
Tan YX; Luo J; Huang JX; Luo DM; Liang HY; Zhou X; Liu XL; Xu N
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):323-329. PubMed ID: 35680632
[No Abstract] [Full Text] [Related]
28. Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Palandri F; Palumbo GA; Abruzzese E; Iurlo A; Polverelli N; Elli E; Bonifacio M; Bergamaschi M; Martino B; Tiribelli M; Benevolo G; Tieghi A; Sgherza N; Isidori A; Binotto G; Crugnola M; Heidel F; Cavazzini F; Bosi C; Auteri G; Cattaneo D; Foà R; Lemoli RM; Cuneo A; Krampera M; Bartoletti D; Cavo M; Vianelli N; Breccia M; Latagliata R
Hematol Oncol; 2019 Oct; 37(4):418-423. PubMed ID: 30985017
[TBL] [Abstract][Full Text] [Related]
29. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.
Kuykendall AT; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e45-e53. PubMed ID: 28869184
[TBL] [Abstract][Full Text] [Related]
30. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M
JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Ruxolitinib versus Best Available Therapy in Treating Primary Myelofibrosis.
Hasan KM; Elmeshhadany AY; Shabila NP
Sultan Qaboos Univ Med J; 2022 Aug; 22(3):393-399. PubMed ID: 36072080
[TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.
Strati P; Abdelrahim M; Selamet U; Page VD; Pierce SA; Verstovsek S; Abudayyeh A
Ann Hematol; 2019 Jul; 98(7):1611-1616. PubMed ID: 31093708
[TBL] [Abstract][Full Text] [Related]
33. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
34. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
Khanal A; Budhathoki N; Singh VP; Shah BK
Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478
[TBL] [Abstract][Full Text] [Related]
35. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Tsukamoto Y; Kiyasu J; Tsuda M; Ikeda M; Shiratsuchi M; Ogawa Y; Yufu Y
Intern Med; 2018 May; 57(9):1297-1300. PubMed ID: 29279479
[TBL] [Abstract][Full Text] [Related]
36. Second primary malignancies in adult acute myeloid leukemia--A US population-based study.
Ghimire KB; Shah BK
Anticancer Res; 2014 Jul; 34(7):3855-9. PubMed ID: 24982414
[TBL] [Abstract][Full Text] [Related]
37. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis.
Barraco F; Greil R; Herbrecht R; Schmidt B; Reiter A; Willenbacher W; Raymakers R; Liersch R; Wroclawska M; Pack R; Burock K; Karumanchi D; Gisslinger H
Br J Haematol; 2020 Dec; 191(5):764-774. PubMed ID: 32583458
[TBL] [Abstract][Full Text] [Related]
38. Risk and survival of second primary malignancies following diagnosis of gastric mucosa-associated lymphoid tissue lymphomas: A population-based study.
Yang Y; Yang Y; Yan S
Curr Probl Cancer; 2021 Dec; 45(6):100735. PubMed ID: 33867153
[TBL] [Abstract][Full Text] [Related]
39. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Palandri F; Auteri G; Abruzzese E; Caocci G; Bonifacio M; Mendicino F; Latagliata R; Iurlo A; Branzanti F; Garibaldi B; Trawinska MM; Cattaneo D; Krampera M; Mulas O; Martino EA; Cavo M; Vianelli N; Impera S; Efficace F; Heidel F; Breccia M; Elli EM; Palumbo GA
Ann Hematol; 2024 Jun; 103(6):1931-1940. PubMed ID: 38478023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
